Android app on Google Play

Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA

May 25, 2012 9:14 AM EDT Send to a Friend
Pfizer (NYSE: PFE) reports that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

Axitinib, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, which are receptors that can influence tumor growth, vascular angiogenesis, and progression of cancer.

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment